The Developmental Therapeutics Program has achieved national recognition as a major center for the development of novel chemotherapy approaches to pediatric cancer treatment.
Texas Children’s Cancer Center has developed a comprehensive program of drug development and clinical and laboratory-based pharmacology that focuses on the preclinical study and clinical development of new agents to treat pediatric malignancies.
Stacey Berg, MD – Co-Chair
Dr. Stacey Berg is involved in preclinical investigations of the pharmacokinetics of new agents. Data is analyzed with a variety of computer modeling strategies. This data facilitates the development of new therapies of children with cancer.
Susan Blaney, MD – Co-Chair, Principal Investigator
Dr. Susan Blaney performs pre-clinical and clinical studies of new antineoplastic agents. A primary focus of her research is the development of new drugs for the treatment of pediatric CNS tumors with a particular emphasis on the development of new agents for intrathecal administration.
Dr. Patricia Baxter’s research focus has been on examining the role of BMI-1 in pediatric brain tumors. Her interests are in pre-clinical and clinical research studies of new therapies for patients with brain tumors.
Dr. Ronald Bernardi has been researching the identification and evaluation of novel therapeutic targets for medulloblastoma, including the use of shRNA genetic screens. He is in the laboratory of Dr. Thomas Westbrook.
Dr. Lisa Bomgaars has experience with pre-clinical and clinical pharmacology research and is a co-investigator on several studies evaluating novel anticoagulation agents for pediatric thrombosis treatment. She has ongoing interests in the area of pharmacogenetically guided warfarin therapy for children.
As a member of the leukemia and lymphoma programs, Dr. Terzah Horton is currently the study coordinator for two Phase I clinical trials as a member of the Developmental Therapeutics team.
Dr. Jodi Muscal’s translational research focuses on the pre-clinical development and clinical application of new and targeted drugs for the treatment of childhood cancers. She is currently exploring multiple new agents for pediatric tumors including an aurora kinase inhibitor.
Kate Mazur is the pediatric nurse practitioner for the Developmental Therapeutics Program.
Sr. Research Coordinator
Leticia H. McGuffey
Clinical Research Associate